Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 17;23(2):51. doi: 10.3892/ol.2021.13169

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Kaito et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 7. — Enhanced ADCC activity of daratumumab following FLT3 inhibitor treatment in AML cells with FLT3-internal tandem duplication. (A) Histograms of CD38 expression in MOLM-13 and MV-4-11 cells. (B) ADCC assay of daratumumab. Target cells (MOLM-13 and MV-4-11) were exposed to quizartinib or DMSO for 48 h before coculture with KHYG-1/CD16 cells. (C) ADCC assay of daratumumab. Target cells (THP-1) were exposed to quizartinib or DMSO for 48 h before coculture with KHYG-1/CD16 cells. Experiments were repeated thrice. Error bars represent the SD. The data were statistically analyzed using a multiple linear regression model. **P<0.01. ADCC, antibody-dependent cellular cytotoxicity; FLT3, FMS-like tyrosine kinase 3; MFI, mean fluorescence intensity; NS, no significant difference.